The Actium Equity Partners (AEP) Fund invests in early- to mid-stage drug and technology companies that fall within the critical window between platform validation and early human proof of principle. We believe we can generate superior returns by investing in and assisting companies with medically important technologies and strong commercial potential.

The Fund seeks out opportunities where investments and our team’s expertise can provide meaningful stimulus to a company approaching an important milestone or commercialization opportunity. Our Partners use their deep operational expertise to critically assist investee companies in achieving major milestones on the path to success, and generating strong returns for the entrepreneurs and investors.

If you would like more information on Actium and the AEP Fund, please contact us.